ENBIS: European Network for Business and Industrial Statistics

Flexible Modeling Of Pre-Clinical Combination Studies

23 September 2009, 11:15 – 11:35

Abstract

Submitted by

Chris Harbron

Authors

Chris Harbron

Affiliation

Discovery Statistics, AstraZeneca

Abstract

There is a strong and increasing interest in the development of drug combination therapies within the
pharmaceutical industry, so a robust evaluation of the potential for compounds to interact synergistically at an
early stage within the pharmaceutical pipeline is clearly of great value.
I will describe a newly developed unified approach for assessing synergy which allows a number of different
assessments to be made and compared under a common framework, powerfully and flexibly using all the available
experimental data and giving a complete description of the studied combination space with statements of
confidence. The method is applicable over wide classes of experimental design and response patterns and is
backed up with informative graphical displays.

View paper

Return to programme